Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Immuron's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Immuron's regulatory disclosures and financial reporting.
Immuron Limited (IMRN) has executed an exclusive distribution agreement with Sweden-based Calmino group AB to launch PROIBS® in the United States. PROIBS®, already launched by Immuron in Australia during FY26, targets part of the U.S. digestive/gut health supplement market, which is valued at $4.16 billion.
PROIBS® is described as a medical device for abdominal pain, bloating and unsettled bowel movements, containing AVH200® from Aloe barbadensis Mill to support the intestinal mucosal barrier and suitable for long-term use. Calmino’s usability study of 1,003 users reported that 94% found PROIBS® helpful, 91% saw improvement in daily life and 98% would recommend it. Immuron positions this agreement as part of a broader commercial growth strategy to expand its digestive health portfolio beyond Travelan®.
Immuron Limited (IMRN) reported preliminary unaudited results for the year ended 30 June 2026. Revenue from contracts with customers was A$7,713,601, up 5.9% from A$7,287,002 in 2025, driven mainly by higher Travelan® sales in Australia and North America. Australian Travelan® revenue rose to A$5,672,501 and U.S. Travelan® revenue to A$1,768,411, while Canadian sales declined.
The loss after tax attributable to shareholders narrowed to A$3,838,699, a 26.4% improvement from A$5,215,987, despite fully expensing A$1,933,440 of research and development. Gross profit increased to A$4,975,072, with a margin of 64.5%, down 0.9 percentage points. Operating cash outflow improved to A$3,259,720 from A$6,136,949, and cash and cash equivalents increased to A$9,017,814, supported by equity issuances. Net tangible asset backing per share slipped slightly to 3.35 cents from 3.45 cents. No dividends were declared, and audited financial statements are expected by the end of September 2026.
Immuron Ltd (IMRN) provided an investor presentation outlining its FY2026 performance and partnering-focused strategy. FY2026 global sales revenue was A$7.7 million, up 6% year on year, with Australian sales of A$5.8 million (up 10%), U.S. sales of A$1.8 million (up 7% and 13% in USD) and Canadian sales of A$0.2 million (down 55%). Cash was A$10.0 million as of 31 December 2025.
The company is repositioning as a commercially focused biopharmaceutical business with over-the-counter products Travelan and ProIBS while seeking partners for its clinical assets IMM-124E (Travelan for traveler’s diarrhea) and IMM-529 (Clostridioides difficile infection). IMM-124E is eligible for an end-of-Phase 2 FDA meeting, and IMM-529 has an FDA-approved investigational new drug application to proceed to Phase 2. Management plans to have licensees fund development and commercialization in exchange for upfront fees, milestones and royalties, aiming to reduce R&D spend and cash burn while maintaining recurring OTC revenue.
Immuron Limited, an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious diseases, reports that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time.
The company highlights its lead product Travelan®, an orally administered passive immunotherapy aimed at reducing the risk of travelers’ diarrhea, and describes its proprietary platform based on hyper-immune bovine colostrum-derived immunoglobulins. Immuron also outlines pipeline asset IMM-529 for recurrent Clostridioides difficile infection and its distribution agreement for ProIBS®, a certified medical device for treating irritable bowel syndrome symptoms in Australia and New Zealand.
Immuron Limited is an Australian biopharmaceutical company developing orally delivered polyclonal antibodies for infectious, gut-mediated diseases. The chief executive officer presented an investor update at the TechKnow Invest Roadshow in Melbourne, outlining recent commercial performance, cash position and partnering plans for its clinical assets.
For FY 2026, global sales revenue was A$7.7 million, up 6% on the prior year, including Australian sales of A$5.8 million (up 10%), U.S. sales of A$1.8 million (up 7%, or 13% in USD), and Canadian sales of A$0.2 million (down 55%). HY 2026 EBITDX (ex‑R&D) was -A$1.1 million, and cash was A$10.0 million at 31 December 2025, described as equivalent to 22.5 months of cash used in operating activities in 1H FY26; an A$1.1 million R&D tax incentive was received in February 2026.
The company markets Travelan for travelers’ diarrhea and ProIBS for irritable bowel syndrome while pursuing partnerships for IMM‑124E and IMM‑529. IMM‑124E (Travelan) is eligible for an end‑of‑Phase 2 FDA meeting, and IMM‑529 for Clostridioides difficile infection has an FDA‑approved investigational new drug application and preclinical survival rates around 80–90% in prevention, treatment and relapse models. Management highlights a strategy to partner these assets, reduce net R&D expense, and focus internal resources on over‑the‑counter sales and portfolio expansion.
Immuron Limited reports that CEO Steven Lydeamore will present at the TechKnow Invest Roadshow in Melbourne on July 27, 2026.
The Australian biopharmaceutical company develops orally delivered targeted polyclonal antibodies, including Travelan for travelers’ diarrhea and IMM-529 for recurrent Clostridioides difficile infection. Its platform uses hyperimmune bovine colostrum to generate antibodies active in the gastrointestinal tract, and it also distributes ProIBS for irritable bowel syndrome in Australia and New Zealand, citing supporting clinical and market data.
Immuron Limited, an Australian biopharmaceutical company focused on orally delivered polyclonal antibodies for infectious and gut-mediated diseases, reported FY26 global sales revenue of A$7.7 million, up 6% on the prior year. Australian sales were A$5.8 million, up 10%, and U.S. sales were A$1.8 million, up 7% (13% in USD), while Canadian sales were A$0.2 million, down 55% with strong growth in 4Q FY26. HY26 EBITDX (ex-R&D) was a loss of A$1.1 million, but improved versus both HY25 and 2H FY25. Cash was A$10.0 million at 31 December 2025, equivalent to more than 22 months of 1H FY26 operating cash use, supported by a A$1.1 million R&D Tax Incentive.
Immuron markets two oral products, Travelan for travelers’ diarrhea risk reduction and ProIBS for irritable bowel syndrome symptoms, generating four consecutive quarters of Travelan sales above the prior year. The company is pursuing a partnering strategy for its clinical assets IMM-124E (eligible for an end of Phase 2 meeting with the U.S. FDA for travelers’ diarrhea) and IMM-529 (oral biologic for C. difficile infection with an FDA-approved IND for Phase 2). Under this model, partners would typically fund development and commercialization in exchange for upfront payments, milestones and royalties, aiming to reduce Immuron’s R&D spend and cash burn while it focuses on over-the-counter commercialization and expanding its distribution and product portfolio.
Immuron Limited reports unaudited FY26 Travelan sales of AUD$7.7 million, up 6% on the prior comparative period, marking four consecutive quarters of growth. Second-half sales were AUD$3.5 million, up 7%, and fourth-quarter sales were AUD$2.0 million, up 2%.
Australia remained the largest market with FY26 sales of AUD$5.8 million, up 10% on pcp, supported by expanded digital marketing, new store listings, and increased South East Asian travel. U.S. FY26 sales reached AUD$1.8 million (USD$1.2 million), up 7% in AUD and 13% in USD, aided by Amazon enhancements and social media campaigns, partly offset by a stronger Australian dollar.
Canada delivered FY26 sales of AUD$0.2 million, down 55% on pcp after a prior-year pipeline fill, but quarterly trends improved, with Q4 FY26 sales up 427% on pcp as promotions and in‑store education built brand awareness. Immuron also outlines its antibody-based platform programs IMM-124E (Travelan), IMM-529 for recurrent C. difficile infection, and distribution of ProIBS for irritable bowel syndrome.
Immuron Limited has engaged life sciences advisory firm Pullan Consulting to help secure a strategic partnership for its IMM-529 program targeting Clostridioides difficile infection (CDI). Pullan has executed between five and twelve partnering transactions annually over the past 20 years.
IMM-529 has FDA Investigational New Drug approval for a Phase 2 trial in CDI, with a planned randomized, double-blind, placebo-controlled study of up to 60 subjects at multiple Australian sites under the fast-track Clinical Trial Notification scheme. An opportunity assessment projects base case yearly revenue of about US$400M if IMM-529 proves efficacious and gains favorable positioning in the treatment algorithm. Preclinical models showed strong prevention and treatment effects, and Immuron is seeking a licensee to fund further development, registration, and commercialization through a typical structure of upfront fees, milestones, and royalties.
Immuron Limited reports that 3,805,528 IMC ordinary fully paid shares have ceased on the ASX as of 29/6/2026. The company paid consideration of AUD 0 per security for this cessation.
After this change, Immuron has 322,848,081 IMC ordinary fully paid shares on issue, along with 3,767,492 IMCAE performance rights and 8,000,000 IMCAI options expiring on various dates at various prices. These figures will be used by the ASX to calculate the company’s market capitalization.